Sign in Subscribe
Cardiology

Pioglitazone Reduces Carotid Artery Thickness in Type 2 Diabetes Patients

Strategic Insights

— 1 min read

Researchers presented the results of a clinical study at the American Heart Association's Scientific Sessions 2004, showing that the medication pioglitazone significantly reduced the thickness of the carotid artery in patients with type 2 diabetes. This is a critical finding, as the thickness of the carotid artery is an indicator of atherosclerotic disease, which may increase the risk of heart attack or stroke. The study involved 173 patients who received either pioglitazone or glimepiride, an older medication for type 2 diabetes, and found that only the pioglitazone group showed a significant reduction in carotid artery thickness.

Key Takeaways:

  • The study involved 173 patients with type 2 diabetes, 66 females and 107 males, with a mean age of 62.6 years and a body mass index (BMI) of 31.8, classified as obese.
  • The patients received either pioglitazone (45 mg/day) or glimepiride (1-6 mg/day) and were measured for carotid intima media thickness (IMT) before and after 12 and 24 weeks of treatment.
  • Only the pioglitazone group showed a significant reduction in carotid IMT, with a mean reduction of -0.033 ± 0.052 mm at 12 weeks and -0.054 ± 0.059 mm at 24 weeks.
  • The glimepiride group showed little to no change in carotid IMT, with a mean change of -0.002 ± 0.047 mm at 12 weeks and -0.011 ± 0.058 mm at 24 weeks.
  • The study suggests that pioglitazone may have benefits beyond improving metabolic control in patients with type 2 diabetes, including potential reductions in cardiovascular disease risk.
  • The population in the study was generally well-tolerated, with both treatments showing minimal side effects.

Statistics:

  • Mean age of patients: 62.6 years
  • Mean BMI of patients: 31.8, classified as obese
  • Number of female patients: 66
  • Number of male patients: 107
  • Total number of patients: 173
  • Dose of pioglitazone: 45 mg/day
  • Dose of glimepiride: 1-6 mg/day
  • Mean reduction in carotid IMT for pioglitazone group at 12 weeks: -0.033 ± 0.052 mm
  • Mean reduction in carotid IMT for pioglitazone group at 24 weeks: -0.054 ± 0.059 mm
  • Mean change in carotid IMT for glimepiride group at 12 weeks: -0.002 ± 0.047 mm
  • Mean change in carotid IMT for glimepiride group at 24 weeks: -0.011 ± 0.058 mm

Sources:

  • "Pioglitazone Reduces Carotid Artery Thickness in Type 2 Diabetes Patients." NewsRx.com & NewsRx.net. 2004 DEC 12.

Read more